Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
in vivo CAR-T therapy
technology8 mentionslast seen Nov 12, 2026
CAR-T cell therapy administered in vivo, discussed as a treatment with barriers to adoption.
Relationships 7
- CREATE Medicinesdevelopsin vivo CAR-T therapy99% confidence2 sources
- in vivo CAR-T therapyapplies toautoimmune disease treatment99% confidence2 sources
- Tempest Therapeutics, Inc.developsin vivo CAR-T therapy99% confidence2 sources
- in vivo CAR-T therapyapplies tocancer treatment92% confidence1 source
- in vivo CAR-T therapyapplies tooncology88% confidence1 source
- Adicet Bio, Inc.developsin vivo CAR-T therapy85% confidence1 source
- in vivo CAR-T therapydepends onCD19 CAR-T80% confidence1 source
Relationship
Tempest Therapeutics, Inc.developsin vivo CAR-T therapy
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 12, 2026Tempest Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease
- filingSEC EDGARSep 28, 2026Tempest Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease